Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
TuberculosisInflammation BiomarkersLiver Function TestsIron StatusMetabolomicsNutritional StatusClinical Outcomes
Interventions
DIETARY_SUPPLEMENT

Omega-3 (EPA+DHA)

In this study omega-3 will be the real thing mega omega supreme capsule, it will be used as an adjunct therapy with TB treatment in the intensive phase of treatment. Participant will receive x3, 1g capsules which will provide approximately 2g of EPA and DHA

DIETARY_SUPPLEMENT

Placebo

This group will receive the placebo, which will be 3 x 1g capsules of high linoleic sunflower oil, the sunflower capsules have been encapsulated to match the dimension of the omega 3 supplement. The capsules will also be given as and adjunct to TB treatment of the intensive phase of TB treatment

Trial Locations (1)

2571

Perinatal HIV research Unit (Matlosana), Klerksdorp

All Listed Sponsors
collaborator

Perinatal HIV Research Unit of the University of the Witswatersrand

OTHER

lead

North-West University, South Africa

OTHER

NCT07118059 - Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial | Biotech Hunter | Biotech Hunter